Clinical trial
Adding New Drugs for HIV Infected Patients Failing Current Therapy
NCT00031044 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00031044 |
|---|---|
| Title | Adding New Drugs for HIV Infected Patients Failing Current Therapy |
| Official title | A Randomized Phase I/II Placebo-controlled Study of Amdoxovir (DAPD) Versus Placebo Together With Enfuvirtide (T-20) Plus Optimized Background Therapy for HIV-Infected Subjects Failing Current Therapy |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Enfuvirtide, Amdoxovir |
| Enrollment | 50 |
| Completion | Nov 1, 2004 |
| First posted | Feb 22, 2002 |
| Last update posted | Nov 1, 2021 |
| Countries | Puerto Rico, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: